A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Ifinatamab deruxtecan (Primary) ; MK 6070 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Jan 2025 New trial record